SEARCH

SEARCH BY CITATION

References

  • 1
    Boner A, Sette L, Martinati L, Sharma R, Richards D. The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis. Allergy 1995;50:498505.
  • 2
    Meltzer EO, Orgel HA, Bronsky EA et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for allergic rhinitis assessed by symptoms, rhinomanometry and nasal cytology. J Allergy Clin Immunol 1990;86:22130.
  • 3
    Pipkorn U, Rundcrantz H, Lundqvist N. Budesonide—a new nasal steroid. Rhinology 1980;18:1715.
  • 4
    Howarth PH. The cellular basis for allergic rhinitis. Allergy 1995;50(Suppl. 23):610.
  • 5
    Fokkens WJ, Godthelp T, Holm AF et al. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: a biopsy study. Clin Exp Allergy 1992;22:70110.
  • 6
    Irani A, Bradford T, Kepley C, Schechter L, Schwartz L. Detection of MC and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989;37:150913.
  • 7
    Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995;151(6):19006.
  • 8
    Juliusson S, Aldenborg F, Enerback L. Proteinase content of mast cells of nasal mucosa: effects of natural allergen exposure and of local corticosteroid treatment. Allergy 1995;50(1):1522 Erratum in: Allergy 1995;50(5):462.
  • 9
    Rak S, Jacobson MR, Sudderick RM et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994;24(10):9309.
  • 10
    Bradding P, Feather IH, Wilson S et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993;151(7):385365.
  • 11
    Klein-Jan A, Severijnen E, Godthelp T, Blom H, Holm A, Fokkens W. IL-4 (protein and mRNA) and inflammatory cells in the nasal mucosa of perennial allergic patients. Mast cells are a major source of IL-4 mRNA; CD15 positive cells (eosinophils) are the principal source of IL-4 protein. Allergologie 1996;19:56.
  • 12
    Holt PG, Oliver J, Bilyk N et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993;177:397407.
  • 13
    Bieber T, de la Salle H, Hanau D, Wollenberg A. Expression of the high-affinity receptor for IgE (Fc epsilon FU) on human Langerhans cells: the end of a dogma. J Invest Dermatol 1992;99(5):10S1S.
  • 14
    Fokkens WJ, Bruijnzeel-Koomen CAFM, Vroom TM et al. The Langerhans cell: an underestimated cell in atopic disease. Clin Exp Allergy 1990;20:62738.
  • 15
    Fokkens WJ, Vroom T, Rijntjes E, Mulder PGH. Fluctuation of the number of CD1a (T6)-positive dendritic cells, presumably Langerhans cells, in the nasal mucosa of patients with isolated grass-pollen allergy before, during, and after the grass-pollen season. J Allergy Clin Imrnunol 1989;84:3943.
  • 16
    Fokkens WJ. Cellular aspects of nasal immunology. Rhinol Suppl 1992;14:326.
  • 17
    Godthelp T, Fokkens W, Klein-Jan A et al. Antigen presenting cells in the nasal mucosa of patients with allergic rhinitis during allergen provocation. Clin Exp Allergy 1996;26:67788.
  • 18
    Juliusson S, Bachert C, Klementsson H, Karlsson G, Pipkorn U. Macrophages on the nasal mucosal surface in provoked and naturally occurring allergic rhinitis. Acta Otolaryngol 1991;111(5):94653.
  • 19
    Holm AF, Fokkens WJ, Godthelp T, Mulder PG, Vroom TM, Rijntjes E. Effect of 3 months' nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. Allergy 1995;50(3):2049.
  • 20
    Godthelp T, Holm A, Blom H et al. A double-blind comparison of two different dosages of fluticasone propionate aqueous nasal spray in the treatment of patients with allergic perennial rhinitis - a biopsy study. Allergologie 1996;19:42.
  • 21
    Holm A, Fokkens W, Godthelp T, Vroom T, Rijntjes E, Fokkens W. Safety and efficacy of one-year treatment with fluticasone propionate on clinical signs and inflammatory cells in the nasal mucosa of allergic perennial rhinitis patients. Allergologie 1996;19:43.
  • 22
    Masuyama K, Jacobson MR, Rak S et al. Topical gluco-corticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994;82(2):1929.
  • 23
    Orgel HA, Meltzer EO, Bierman CW et al. Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy. J Allergy Clin Immunol 1991;88(2):25764.